SCHEMBL6134973

SCHEMBL6134973

Cc1ccc(S(=O)(=O)NC(=O)c2ccc3nc(C)n(Cc4ccc(Cl)cc4Cl)c3c2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.70
FLT1 P17948 11/20 0.53
FLT4 P35916 11/20 0.53
KDR P35968 11/20 0.53
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC10 Q969S8 2/20 0.45
HDAC11 Q96DB2 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC9 Q9UKV0 2/20 0.45
HDAC5 Q9UQL6 2/20 0.45
LMNA P02545 1/20 0.43
PTGS2 P35354 1/20 0.43
EGFR P00533 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1160394 0.93 PPARG (0.70) PPARGFLT1FLT4KDRHDAC3
Hydrochloric Acid SCHEMBL6171221 0.92 PPARG (0.69) PPARGFLT1FLT4KDRHDAC3
SCHEMBL6303641 0.91 PPARG (0.58) PPARGFLT1FLT4KDRHDAC3
SCHEMBL7655927 0.91 PPARG (0.58) PPARGFLT1FLT4KDRHDAC3
SCHEMBL1160331 0.91 PPARG (0.57) PPARGFLT1FLT4KDRHDAC3
SCHEMBL7653691 0.91 PPARG (0.65) PPARGFLT1FLT4KDRHDAC3
SCHEMBL7650293 0.91 PPARG (0.65) PPARGFLT1FLT4KDRHDAC3
SCHEMBL6303697 0.90 PPARG (0.60) PPARGFLT1FLT4KDRHDAC3
SCHEMBL6304196 0.90 PPARG (0.67) PPARGFLT1FLT4KDRHDAC3
SCHEMBL6303634 0.90 PPARG (0.57) PPARGFLT1FLT4KDRHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP claimed
WO-2005082414-A2 CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT ASTELLAS PHARMA INC. (JP) 2005-09-09 WO disclosed
US-20050197376-A1 Concomitant drugs FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-09-08 US disclosed
US-6420409-B1 GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
EP-1020452-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-07-19 EP disclosed